Close Menu
Home › Owlstone Medical, 4D Pharma Sign Breath Biomarker Services Deal

Owlstone Medical, 4D Pharma Sign Breath Biomarker Services Deal

Mar 07, 2017

NEW YORK (360Dx) – British diagnostics firm Owlstone Medical announced today that it has signed an agreement to provide breath biomarker services to 4D Pharma to assist with its drug-development efforts.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
24
Featured Webinar

Metabolomics Analyses to Elucidate Systemic Processes in Human Health and Disease

Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

May
22
Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

What's Popular?

In Business News

  1. Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

  2. Natera Prices $100M Stock Offering

  3. Natera Files for Proposed $100M Stock Offering, Expects Q1 Revenues of $65M-$67M

  4. Danaher Q1 Revenues Up 4 Percent

  5. Abbott Q1 Diagnostics Revenues Flat

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.